Comprehensive mutational profiling of core binding factor acute myeloid leukemia

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• Core Binding Factor Acute Myeloid Leukemia (CBF-AML), encompassing t(8;21) and inv(16) translocations, exhibits significant clinical and biological heterogeneity.
• Relapse rates in CBF-AML can reach up to 40%, highlighting the need for better prognostic markers and understanding of disease pathogenesis.
• CBF translocations alone are insufficient for AML development, indicating the crucial role of cooperating mutations.

Purpose of the Study:

• To investigate the spectrum of coexisting mutations in CBF-AML subtypes using high-throughput sequencing.
• To identify distinct mutational profiles between t(8;21) AML and inv(16) AML.
• To correlate specific mutations and their allele ratios with clinical outcomes and prognosis in CBF-AML patients.

Main Methods:

• Extensive mutational analysis by high-throughput sequencing was performed on 215 CBF-AML patients (age 1-60 years) from clinical trials.
• Investigated mutations in genes related to tyrosine kinase signaling (KIT, N/KRAS, FLT3), chromatin regulation, and cohesin complex.
• Correlated mutation status and mutant allele ratios with patient prognosis.

Main Results:

• Mutations in tyrosine kinase signaling genes (KIT, N/KRAS, FLT3) were frequent in both CBF-AML subtypes.
• Genes regulating chromatin or encoding cohesin complex members were highly frequent in t(8;21) AML (42% and 18%) but rare in inv(16) AML.
• High KIT mutant allele ratios indicated poor prognosis in t(8;21) AML, while high N/KRAS ratios suggested a favorable outcome without KIT/FLT3 mutations.
• Mutations in epigenetic or cohesin genes worsened prognosis in patients with tyrosine kinase pathway mutations, suggesting synergistic effects.

Conclusions:

• CBF-AML pathogenesis is influenced by diverse cooperating mutations, leading to distinct clinical behaviors between t(8;21) and inv(16) subtypes.
• Specific mutation profiles, such as those involving chromatin modifiers and cohesin complex, characterize t(8;21) AML and impact prognosis.
• The interplay between tyrosine kinase signaling mutations and epigenetic/cohesin mutations offers potential therapeutic targets and prognostic indicators in CBF-AML.